Beeinflusst die Verdünnung das kosmetische Ergebnis von BoNT/A?

Abstract

Complex-protein-free botulinum neurotoxin type A in both dilutions effectively reduced severity of glabellar lines. There was no statistically significant difference in efficacy between the two dilutions.

A Randomized, Comparative Study to Evaluate Efficacy and Safety of Two Injection Volumes of AbobotulinumtoxinA in Treatment of Glabellar Lines

“…8,9 Another comparative study involving 40 patients used 5 injection points of 5 U incobotulinumtoxinA in either 0.125 or 0.2 mL per injection point to treat glabellar lines and found no difference in response rate between the 2 treatment groups. 10 …”

The Convergence of Medicine and Neurotoxins: A Focus on Botulinum Toxin Type A and Its Application in Aesthetic Medicine—A Global, Evidence-Based Botulinum Toxin Consensus Education Initiative

“…Despite a fivefold difference in concentration between the two dilutions, no significant differences in efficacy or duration of effect were observed . A study of two different dilutions of BoNTA‐INCO in the glabellar lines also found no significant clinical differences in results …”

Comparison of Two Botulinum Toxin Type A Preparations for Treating Crow's Feet: A Split-Face, Double-Blind, Proof-of-Concept Study

“…Blümel and colleagues confirmed in an animal study that there was no neutralizing antibody formation against BoNTA, even after administration of high doses at short injection intervals 16,17 . There are now also a number of clinical studies published examining the aesthetic use of BoNTA, including treatment of periorbital lines 18–22 …”

“…16,17 There are now also a number of clinical studies published examining the aesthetic use of BoNTA, including treatment of periorbital lines. [18][19][20][21][22] Comparative studies between BoNTA and BTXCo have only been performed for neurological conditions such as torticollis and blepharospasm. Five clinical trials (phase I-III) with more than 800 patients have indicated high efficacy and good tolerability for BoNTA and BTXCo at a dose ratio of 1:1.…”